Jan. 22 (UPI) — The Meals and Drug Management has improved its authorization of the antiviral drug remdesivir to a few COVID-19 outpatients.
The FDA took two movements Friday to extend the use of the antiviral drug created by means of Gilead Sciences biopharmaceutical company “to positive non-hospitalized adults and pediatric patients for the remedy of delicate-to-average COVID-19 disease,” in step with a statement.
Advertisement